Neurodiagnostics market projected to double by 2035

The global neurodiagnostics market is expected to grow from $10.52 billion in 2026 to $20.36 billion by 2035, driven by AI-enabled workflows, government neurotech funding and a shift toward blood-based biomarkers. The report points to aging populations, broader reimbursement and outpatient testing as the main forces reshaping diagnosis of neurological disease.

Why it matters: - The neurodiagnostics market is moving from a specialized imaging category to a broader diagnostic workflow spanning imaging, biomarker testing and AI analytics. - Growth is being driven by structural demand from aging populations and neurological disease, not by short-term healthcare spending cycles. - Faster, less invasive blood-based tests could expand early detection of Alzheimer's and other neurodegenerative diseases.

What happened: - Market Research Future projected the global neurodiagnostics market will reach $20.36 billion by 2035, up from $10.52 billion in 2026. - The forecast implies a 7.6% compound annual growth rate from 2026 to 2035. - The market base was estimated at $9.78 billion in 2025. - The report was published June 24, 2026.

The details: - Government funding is supporting the market's growth. - The U.S. National Institutes of Health committed more than $12 billion to the BRAIN Initiative through 2026. - The European Commission's Horizon Europe program allocated EUR 1.8 billion for neuroscience and digital-health research through 2027. - The World Health Organization projects the global population age 65 and older will rise from 761 million in 2021 to 1.6 billion by 2050. - Alzheimer's disease affects an estimated 55 million people worldwide, with annual diagnostic and care costs above $1.3 trillion. - The FDA cleared 171 AI-enabled medical devices in 2023, with neurology and radiology among the key areas. - AI tools are being used to triage neuroimaging studies and identify neurological anomalies. - Blood-based biomarkers, especially phosphorylated-tau p-tau217 assays, are moving from research into clinical use. - Several commercial p-tau217 assays received FDA clearance in 2025. - PET scans can cost more than $5,000, while blood-based panels are priced around $200 to $400 per test. - The market is expected to integrate these tests into routine diagnostic workups during 2026 to 2028. - Reagents and consumables led the product mix with about 54.6% revenue share in 2025. - Instruments and systems generated $3.12 billion in 2025. - Neuroimaging technologies accounted for $6.19 billion in 2025. - Neuroinformatics and AI analytics are the fastest-growing technology category, with a 12.3% CAGR from 2026 to 2035. - Neurodegenerative diseases were the largest indication, with about 37.3% revenue share in 2025. - Sleep disorders are the fastest-growing condition segment, at 11.2% CAGR. - Cerebrovascular disorders generated $2.14 billion in 2025. - Hospitals and surgical centers held about 55.4% of the end-user market in 2025. - Diagnostic laboratories and imaging centers generated $2.48 billion in 2025.

Between the lines: - The market is shifting toward diagnostics that fit into cloud-connected, real-time clinical workflows. - That shift favors vendors that can combine imaging hardware, software and biomarkers in one platform. - The move away from invasive imaging toward blood tests could pressure older PET-centric workflows over time. - Regional reimbursement and procurement rules are becoming as important as clinical demand in shaping adoption. - The competitive landscape is moderately concentrated, with the top five companies expected to capture 48% to 55% of global revenue. - M&A has accelerated since 2023 as incumbents buy AI analytics firms to strengthen digital portfolios.

What's next: - The report expects AI-autonomous diagnostic reporting to become a major operating model by 2030. - Human-in-the-loop oversight is expected to remain in place even as AI handles high-volume triage and preliminary reads. - Wearable EEG patches and home sleep-study kits are likely to expand remote and ambulatory monitoring in the early 2030s. - Payers are expected to keep pushing outpatient-first care pathways, which could widen the market beyond hospitals and labs. - Siemens Healthineers, GE HealthCare, Philips Healthcare and Nihon Kohden are positioned as major competitors in imaging, informatics and electrophysiology. - Siemens Healthineers introduced the MAGNETOM Free.XL in December 2025. - GE HealthCare expanded its AIR Recon DL platform across nearly all anatomical imaging in 2024 and 2025. - Philips Healthcare continued to build an integrated diagnostics-to-informatics workflow around Ingenia MRI, Neuro Suite and IntelliSpace. - Nihon Kohden remained a leading electrophysiology specialist with its EEG-1200 series and Neurofax platform.

The bottom line: - Neurodiagnostics is evolving into a faster, cheaper and more software-driven market, with AI and blood-based biomarkers reshaping how neurological disease is detected and monitored.